register

News & Trends - Pharmaceuticals

New PBS listings to counter short bowel syndrome and upper limb spasticity

Health Industry Hub | September 26, 2019 |

Effective 1 October 2019 patients with intestinal failure associated with Short Bowel Syndrome (SBS), and those suffering spasticity in the upper limbs, will have access to greater medicinal support on the Pharmaceutical Benefits Scheme (PBS).

Short Bowel Syndrome is a disorder that arises from an inability to absorb food nutrients and fluid across the gastrointestinal tract, and one that is often caused by surgical removal of all or part of the small intestine.

Australians experiencing SBS will be able to purchase first time listing Revestive (Teduglutide), a medicine that improves the absorption of nutrients and fluid from the gut.

Up to 70 patients per year will benefit from the listing, with the PBS subsidy saving patients up to $284,700 per year for treatment. 

In addition, the current listing of Dysport (clostridium Botulinum Type A Toxin – Haemagglutinin C Complex) will be extended to include patients with moderate to severe spasticity of the upper limbs, following an acute event.

Dysport temporarily relaxes overactive or contracting muscles, and resolves stiffness in the arm and/or hand.

Up to 6,600 patients per year will benefit from the listing. Without the PBS subsidy, patients might pay more than $9,700 per course of treatment.

You may also like New Pharmacy Practice Review on opioids aims to reduce harms from long term use


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.